Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs MPLX LP (MPLX) Price & Performance

Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs MPLX LP — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while MPLX LP trades at $59.9 (market cap $60.12B). The key difference: MPLX LP is far larger — about 3.6× Medpace Holdings Inc's market cap, and MPLX LP pays a 7.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPMPLX
Market Cap
$16.90B$60.12B
Sector
TechnologyTechnology
52-Week High
$620.59$60.51
52-Week Low
$393.42$47.80
Enterprise Value
$16.52B$85.22B
Dividend Yield
7.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

MPLX LP

MPLX trades at $59.94, up 2.11% today, with a bullish technical signal from moving averages and a consensus analyst price target of $61.50. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly earnings have missed expectations. A recent $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) supports growth initiatives, while a 7.3% dividend yield attracts income investors.

Outlook remains positive given fee-based revenue stability and growth projects, but risks include execution challenges from higher capital spending and leverage. Analyst sentiment is strongly bullish with no sell ratings, though investors should monitor earnings consistency and debt levels amid volatile energy markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

Read more on MPLX